{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:31:57Z","timestamp":1778509917046,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Docetaxel is a microtubule inhibitor indicated for the treatment of multiple cancers as a single agent or in combination with other antineoplastics. The U.S. Food and Drug Administration (FDA) conducted a postmarketing review of fatal neutropenic enterocolitis cases reported with docetaxel using the FDA Adverse Event Reporting System (FAERS) and literature to determine whether the drug was a potential cause. We searched FAERS and the literature for reports of fatal neutropenic enterocolitis with docetaxel-based treatment reported between 14 May 1996 and 13 March 2017. We characterized the clinical course and severity of neutropenic enterocolitis and utilized the World Health Organization-Uppsala Monitoring Centre rubric to assess drug causality. We identified 41 fatal cases of neutropenic enterocolitis with docetaxel from FAERS and the literature. The median time to onset of neutropenic enterocolitis from last docetaxel dose was seven days (range 2\u201313 days), and median time to death was nine days (range 3\u201323 days). The cause of death in 83% (34\/41) of patients was neutropenic enterocolitis. We determined the drug-event association as probable in seven cases. Neutropenic enterocolitis with docetaxel monotherapy occurred in six cases; however, in 85% (35\/41) of cases, neutropenic enterocolitis occurred when docetaxel was used in combination with other cytotoxic chemotherapy. In some cases, neutropenic enterocolitis occurred despite use of granulocyte colony-stimulating factors. Neutropenic enterocolitis is a severe and potentially fatal complication of docetaxel-based treatment, especially when combined with other antineoplastic treatments known to cause neutropenia. Practitioners should be aware of this safety risk to promptly recognize and manage patients.<\/jats:p>","DOI":"10.1177\/1078155219879494","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T01:48:36Z","timestamp":1570585716000},"page":"923-928","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Fatal neutropenic enterocolitis associated with docetaxel use: A review of cases reported to the United States Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1177","volume":"26","author":[{"given":"Pritpal","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-1165","authenticated-orcid":false,"given":"Afrouz","family":"Nayernama","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Christopher Jones","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laleh","family":"Amiri Kordestani","sequence":"additional","affiliation":[{"name":"Division of Oncology Products, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Fedenko","sequence":"additional","affiliation":[{"name":"Division of Oncology Products, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Prowell","sequence":"additional","affiliation":[{"name":"Division of Oncology Products, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J","family":"Bersoff-Matcha","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"bibr1-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00442.x"},{"key":"bibr2-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-006-0055-z"},{"key":"bibr3-1078155219879494","first-page":"718","volume":"62","author":"Mehdi I","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"bibr4-1078155219879494","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i1.42"},{"key":"bibr5-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2008.061"},{"key":"bibr6-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis998"},{"key":"bibr7-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920101)69:1<17::AID-CNCR2820690106>3.0.CO;2-X"},{"key":"bibr8-1078155219879494","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS), www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance?AdverseDrugEffects\/default.htm (accessed 26 September 2019)."},{"key":"bibr9-1078155219879494","unstructured":"WHO-UMC system for standardization case causality assessment, www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf (accessed 5 April 2017)."},{"key":"bibr10-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.15.1078"},{"key":"bibr11-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2003.11.018"},{"key":"bibr12-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06195-4"},{"key":"bibr13-1078155219879494","unstructured":"Doxorubicin [Package Insert]. Bridgewater, NJ: Amneal Biosciences LLC, 2017."},{"key":"bibr14-1078155219879494","unstructured":"Cyclophosphamide [Package Insert]. Deerfield, IL: Baxter Healthcare Corporation, 2014."},{"key":"bibr15-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4451"},{"key":"bibr16-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.5391"},{"key":"bibr17-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216"},{"key":"bibr18-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00011-X"},{"key":"bibr19-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1238"},{"key":"bibr20-1078155219879494","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"bibr21-1078155219879494","unstructured":"Taxotere [Package Insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, 2018."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219879494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219879494","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219879494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:00Z","timestamp":1777688520000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219879494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1078155219879494"],"URL":"https:\/\/doi.org\/10.1177\/1078155219879494","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,8]]}}}